Alnylam Pharmaceuticals and Viz.ai partner to develop an AI-enabled care pathway to improve early detection and diagnosis of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), an underdiagnosed cause of heart failure.
Written By: Pharmacally Medical News Desk
Alnylam Pharmaceuticals has announced a collaboration with Viz.ai to develop an artificial intelligence (AI)-enabled care pathway aimed at improving early detection and coordinated management of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed cause of heart failure.
ATTR-CM occurs when misfolded transthyretin proteins accumulate as amyloid deposits in the heart, leading to progressive cardiomyopathy. Despite growing awareness and therapeutic advances, the condition frequently goes undiagnosed for years because its symptoms overlap with other forms of heart disease. Earlier and more accurate detection is considered critical to enabling timely treatment and improving patient outcomes.
Under the collaboration, the companies plan to integrate AI-driven detection tools into routine clinical workflows. The planned pathway will combine an FDA-cleared echocardiography AI algorithm developed by Us2.ai with electronic health record connectivity to help clinicians identify potential ATTR-CM cases earlier and facilitate timely referral and evaluation across cardiology and heart failure teams.
Viz.ai said the initiative will establish a dedicated cardiac amyloidosis care pathway within its clinical workflow platform, using advanced imaging analysis and generative AI to review routine echocardiograms and flag patterns suggestive of disease. The system is designed to guide clinicians through guideline-based diagnostic steps and support coordinated confirmatory testing, referrals, and follow-up across care teams.
“ATTR-CM is often diagnosed too late, when the disease has already progressed significantly,” said Sameer Bansilal, M.D., M.S., Vice President and Global TTR Medical Lead at Alnylam. “Earlier recognition can significantly alter the course of the disease, which is why improving detection and care coordination is critical for patients.”
The collaboration will also support the AI-Enhanced Echocardiography Workflow to Advance Recognition and Diagnosis of Cardiac Amyloidosis (AWARE) study, a prospective implementation study designed to evaluate how AI-enabled screening tools can be incorporated into real-world clinical settings. The study will assess their impact on diagnostic timelines, clinical decision-making, and care coordination in patients suspected of having ATTR-CM.
The initiative is expected to launch later this year across five pilot health systems in the United States, representing diverse clinical environments. Insights generated from the program are intended to guide broader adoption of AI-enabled diagnostic pathways across healthcare networks.
Transthyretin amyloidosis (ATTR) is estimated to affect about 350,000 people worldwide, though roughly 80% of cases remain undiagnosed. By combining AI-enabled detection technologies with coordinated care pathways, Alnylam aims to shift diagnosis earlier in the disease course and improve access to appropriate care for patients with ATTR-CM.
Reference
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association, 24 March 2026, Alnylam Pharmaceuticals Press Release | Mar 24, 2026 | Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the Americ
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis, 24 March 2026, https://www.viz.ai/news/viz-ai-partners-with-alnylam-pharmaceuticals-to-advance-earlier-identification-and-care-coordination-in-cardiac-amyloidosis